Conatus Pharmaceuticals (CNAT) Given a $14.00 Price Target at Oppenheimer

Oppenheimer set a $14.00 target price on Conatus Pharmaceuticals (NASDAQ:CNAT) in a research note released on Thursday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research firms have also recently weighed in on CNAT. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, February 27th. ValuEngine raised shares of Conatus Pharmaceuticals from a sell rating to a hold rating in a report on Friday, March 2nd. Roth Capital started coverage on shares of Conatus Pharmaceuticals in a report on Thursday, February 8th. They issued a buy rating and a $20.00 price target on the stock. HC Wainwright reissued a buy rating and issued a $17.00 price target on shares of Conatus Pharmaceuticals in a report on Thursday, March 8th. Finally, S&P Equity Research increased their price target on shares of Conatus Pharmaceuticals from $5.02 to $5.69 in a report on Wednesday, January 24th. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $12.00.

How to Become a New Pot Stock Millionaire

Conatus Pharmaceuticals stock traded down $0.04 during trading hours on Thursday, hitting $4.08. The company had a trading volume of 1,561,848 shares, compared to its average volume of 670,378. The stock has a market cap of $180.66, a P/E ratio of -6.44 and a beta of 1.16. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 0.47. Conatus Pharmaceuticals has a one year low of $3.85 and a one year high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Wednesday, March 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. The firm had revenue of $8.80 million for the quarter, compared to analysts’ expectations of $9.60 million. Conatus Pharmaceuticals had a negative net margin of 49.17% and a negative return on equity of 61.58%. equities analysts anticipate that Conatus Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN increased its holdings in shares of Conatus Pharmaceuticals by 3,098.0% during the third quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 18,588 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Conatus Pharmaceuticals by 156.4% during the third quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 14,700 shares during the period. Stone Ridge Asset Management LLC bought a new position in shares of Conatus Pharmaceuticals during the fourth quarter worth approximately $143,000. California State Teachers Retirement System bought a new position in shares of Conatus Pharmaceuticals during the second quarter worth approximately $261,000. Finally, Macquarie Group Ltd. bought a new position in shares of Conatus Pharmaceuticals during the third quarter worth approximately $330,000. 39.49% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Conatus Pharmaceuticals (CNAT) Given a $14.00 Price Target at Oppenheimer” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3335987/conatus-pharmaceuticals-cnat-given-a-14-00-price-target-at-oppenheimer.html.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Menlo Therapeutics  Expected to Post Earnings of -$0.68 Per Share
Menlo Therapeutics Expected to Post Earnings of -$0.68 Per Share
MaidSafeCoin  Trading Up 18.7% Over Last Week
MaidSafeCoin Trading Up 18.7% Over Last Week
Quantstamp  Price Up 27.7% Over Last Week
Quantstamp Price Up 27.7% Over Last Week
PokeCoin Price Tops $0.0001 on Major Exchanges
PokeCoin Price Tops $0.0001 on Major Exchanges
Analysts Anticipate Red Robin  Will Post Earnings of $0.72 Per Share
Analysts Anticipate Red Robin Will Post Earnings of $0.72 Per Share
$231.55 Million in Sales Expected for EQT Midstream Partners  This Quarter
$231.55 Million in Sales Expected for EQT Midstream Partners This Quarter


Leave a Reply

© 2006-2018 Ticker Report. Google+.